CONSOLIDATED CONDENSED BALANCE SHEETS - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Current assets
Cash and cash equivalents	$ 3,140.6	$ 3,045.2
Short-term investments (Note 5)	757.9	930.7
Accounts receivable, net of allowances of $12.6 and $11.6, respectively	669.2	609.1
Other receivables	82.7	118.3
Inventories (Note 2)	1,113.9	1,086.7
Prepaid expenses	111.3	121.0
Other current assets	304.5	347.6
Current assets of discontinued operations (Note 4)	32.6	26.8
Total current assets	6,212.7	6,285.4
Long-term investments (Note 5)	277.9	307.9
Property, plant, and equipment, net	1,698.3	1,686.0
Operating lease right-of-use assets	96.9	98.2
Goodwill	1,778.7	1,776.7
Other intangible assets, net	1,174.9	1,176.6
Deferred income taxes	1,027.8	992.1
Other assets (Note 2)	742.7	721.6
Non-current assets of discontinued operations (Note 4)	12.4	10.8
Total assets	13,022.3	13,055.3
Current liabilities
Accounts payable	172.4	197.4
Accrued and other liabilities (Note 2)	1,196.4	1,282.4
Operating lease liabilities	23.7	23.4
Current liabilities of discontinued operations (Note 4)	2.3	2.0
Total current liabilities	1,394.8	1,505.2
Long-term debt	597.8	597.7
Operating lease liabilities	77.9	78.9
Uncertain tax positions	402.6	384.6
Other liabilities	357.6	426.0
Total liabilities	2,830.7	2,992.4
Commitments and contingencies (Note 11)
Stockholders' equity
Preferred stock, $0.01 par value, authorized 50.0 shares, no shares outstanding	0.0	0.0
Common stock, $1.00 par value, 1,050.0 shares authorized, 655.9 and 654.8 shares issued, and 586.2 and 588.6 shares outstanding, respectively	655.9	654.8
Additional paid-in capital	2,653.2	2,613.4
Retained earnings	13,525.0	13,167.0
Accumulated other comprehensive loss (Note 12)	(254.5)	(244.5)
Treasury stock, at cost, 69.7 and 66.2 shares, respectively	(6,450.9)	(6,192.3)
Total Edwards Lifesciences Corporation stockholders' equity	10,128.7	9,998.4
Noncontrolling interest	62.9	64.5
Total stockholders' equity	10,191.6	10,062.9
Total liabilities and equity	$ 13,022.3	$ 13,055.3